-
EXECUTIVE SUMMARY
-
MARKET ATTRACTIVENESS ANALYSIS 18
-
MARKET INTRODUCTION
-
DEFINITION 19
-
SCOPE OF THE STUDY 19
-
RESEARCH OBJECTIVE 19
-
MARKET STRUCTURE 19
-
ASSUMPTIONS & LIMITATIONS 20
-
RESEARCH METHODOLOGY
-
DATA MINING 21
-
SECONDARY RESEARCH 22
-
PRIMARY
-
RESEARCH 23
-
BREAKDOWN OF PRIMARY RESPONDENTS 24
-
FORECASTING
-
TECHNIQUES 25
-
RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 26
- BOTTOM-UP APPROACH 27
- TOP-DOWN APPROACH 27
-
DATA TRIANGULATION 28
-
VALIDATION 28
-
MARKET DYNAMICS
-
OVERVIEW 29
-
DRIVERS 30
- INCREASING PREVALENCE
-
OF DIABETES AND KIDNEY STONES 30
-
LAUNCH OF COMBINATION DRUGS 30
-
RESTRAINTS 31
- COMPLEX REGULATORY REQUIREMENTS 31
-
OPPORTUNITIES 32
- FOCUS ON EMERGING ECONOMIES AND BOOSTING
-
R&D 32
-
MARKET FACTOR ANALYSIS
-
VALUE CHAIN ANALYSIS
- R&D AND DESIGNING 34
- MANUFACTURING 34
- DISTRIBUTION & SALES 34
- POST-SALES SERVICES 34
-
PORTER’S FIVE FORCES MODEL 35
- BARGAINING POWER
-
OF SUPPLIERS 36
-
BARGAINING POWER OF BUYERS 36
-
THREAT OF NEW ENTRANTS 36
-
THREAT OF SUBSTITUTES 36
-
RIVALRY 36
-
IMPACT ANALYSIS OF COVID-19 ON URINARY TRACT INFECTION
-
MARKET 37
-
OVERVIEW 37
- IMPACT ON SUPPLY CHAIN 37
- IMPACT ON PRODUCTION 38
-
GLOBAL URINARY TRACT INFECTION
-
MARKET BY DRUG CLASS
-
OVERVIEW 40
-
QUINOLONES 42
-
Β-LACTAM & CEPHALOSPORINS 43
-
AMINOGLYCOSIDES
-
PENICILLIN 44
-
AZOLES 45
-
GLOBAL URINARY
-
TRACT INFECTION MARKET BY APPLICATION
-
OVERVIEW 46
-
URETHRITIS 47
-
CYSTITIS 48
-
PYELONEPHRITIS 48
-
GLOBAL URINARY TRACT INFECTION MARKET BY PATHOGEN
-
OVERVIEW 49
-
ESCHERICHIA COLI 50
-
STAPHYLOCOCCUS SAPROPHYTICUS 51
-
KLEBSIELLA PNEUMONIAE 51
-
PROTEUS MIRABILIS 52
-
ENTEROCOCCUS FAECALIS 52
-
GLOBAL URINARY TRACT INFECTION MARKET
-
BY END USER
-
OVERVIEW 53
-
HOSPITALS 54
-
CLINICS 54
-
SELF-ADMINISTERED 55
-
GLOBAL URINARY TRACT
-
INFECTION MARKET BY REGION
-
OVERVIEW 56
-
AMERICAS
- NORTH AMERICA 61
-
CANADA 67
-
LATIN AMERICA 70
-
EUROPE 73
- WESTERN EUROPE 76
- EASTERN EUROPE
-
ASIA-PACIFIC 101
- CHINA 105
-
INDIA 108
-
JAPAN 111
- AUSTRALIA 114
-
SOUTH KOREA 117
-
REST OF ASIA-PACIFIC 120
-
MIDDLE
-
EAST & AFRICA 123
-
MIDDLE EAST 126
- AFRICA
-
COMPETITIVE LANDSCAPE
-
OVERVIEW 132
-
COMPETITIVE BENCHMARKING 133
-
GLOBAL URINARY TRACT INFECTION MARKET:
-
COMPANY RANKING, 2020 134
-
KEY DEVELOPMENTS & GROWTH STRATEGIES
- PRODUCT APPROVALS AND LAUNCHES 134
- ACQUISITIONS
-
FINANCIAL MATRIX 135
-
COMPANY PROFILES
-
PFIZER INC. 136
- COMPANY OVERVIEW 136
-
FINANCIAL OVERVIEW 137
-
PRODUCTS/SERVICES OFFERED 138
- KEY DEVELOPMENTS 138
- SWOT ANALYSIS 138
-
KEY STRATEGIES 139
-
NOVO NORDISK A/S 140
- COMPANY
-
OVERVIEW 140
-
FINANCIAL OVERVIEW 140
- PRODUCTS/SERVICES
-
OFFERED 141
-
KEY DEVELOPMENTS 141
- SWOT ANALYSIS
- KEY STRATEGIES 141
-
NOVARTIS AG 142
- COMPANY OVERVIEW 142
- FINANCIAL OVERVIEW 142
- PRODUCTS/SERVICES OFFERED 143
- KEY DEVELOPMENTS 143
- SWOT ANALYSIS 143
- KEY STRATEGIES 144
-
MERCK & CO., INC. 145
-
COMPANY OVERVIEW 145
-
FINANCIAL OVERVIEW 145
-
PRODUCTS/SERVICES OFFERED 146
- KEY DEVELOPMENTS 146
- SWOT ANALYSIS 146
-
KEY STRATEGIES 146
-
ELI LILY AND COMPANY 147
- COMPANY
-
OVERVIEW 147
-
FINANCIAL OVERVIEW 147
- PRODUCTS/SERVICES
-
OFFERED 148
-
KEY DEVELOPMENTS 148
- SWOT ANALYSIS
- KEY STRATEGIES 148
-
ALLERGAN 149
-
COMPANY OVERVIEW 149
-
FINANCIAL OVERVIEW 149
-
PRODUCTS/SERVICES OFFERED 150
-
KEY DEVELOPMENTS 150
-
SWOT ANALYSIS 150
-
KEY STRATEGIES 150
-
CIPLA INC.
- COMPANY OVERVIEW 151
- FINANCIAL OVERVIEW
- PRODUCTS/SERVICES OFFERED 151
- KEY DEVELOPMENTS
- SWOT ANALYSIS 152
- KEY STRATEGIES 152
-
TEVA PHARMACEUTICALS 153
- COMPANY OVERVIEW 153
- FINANCIAL OVERVIEW 153
- PRODUCTS/SERVICES OFFERED
- KEY DEVELOPMENTS 154
- SWOT ANALYSIS 154
- KEY STRATEGIES 155
-
GLAXOSMITHKLINE PLC 156
- COMPANY OVERVIEW 156
- FINANCIAL OVERVIEW 156
- PRODUCTS/SERVICES OFFERED 157
- KEY DEVELOPMENTS 157
- SWOT ANALYSIS 157
- KEY STRATEGIES 157
-
BAYER AG 158
-
COMPANY OVERVIEW 158
- COMPANY
-
VALUE 158
-
FINANCIAL OVERVIEW 159
- PRODUCTS/SERVICES
-
OFFERED 159
-
KEY DEVELOPMENTS 159
- SWOT ANALYSIS
- KEY STRATEGIES 160
-
APPENDIX
-
REFERENCES 161
-
RELATED REPORTS 161
-
LIST OF TABLES
-
INTERVIEWS AND INFORMATION GATHERING PROCESS 23
-
TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 41
-
GLOBAL URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY REGION, 2020-2027 (USD
-
MILLION) 42
-
BY TYPE, 2020-2027 (USD MILLION) 42
-
MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY REGION, 2020-2027 (USD MILLION)
-
CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 43
-
TRACT INFECTION MARKET, FOR AMINOGLYCOSIDES, BY REGION, 2020-2027 (USD MILLION)
-
REGION, 2020-2027 (USD MILLION) 44
-
MARKET, FOR AZOLES, BY REGION, 2020-2027 (USD MILLION) 45
-
URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 47
-
(USD MILLION) 47
-
CYSTITIS, BY REGION, 2020-2027 (USD MILLION) 48
-
TRACT INFECTION MARKET, FOR PYELONEPHRITIS, BY REGION, 2020-2027 (USD MILLION) 48
-
MILLION) 50
-
COLI, BY REGION, 2020-2027 (USD MILLION) 50
-
INFECTION MARKET, FOR STAPHYLOCOCCUS SAPROPHYTICUS, BY REGION, 2020-2027 (USD MILLION)
-
BY REGION, 2020-2027 (USD MILLION) 51
-
MARKET, FOR PROTEUS MIRABILIS, BY REGION, 2020-2027 (USD MILLION) 52
-
GLOBAL URINARY TRACT INFECTION MARKET, FOR ENTEROCOCCUS FAECALIS, BY REGION,
-
2027 (USD MILLION) 52
-
BY END USER, 2020-2027 (USD MILLION) 54
-
INFECTION MARKET, FOR HOSPITALS, BY REGION, 2020-2027 (USD MILLION) 54
-
(USD MILLION) 54
-
SELF-ADMINISTERED, BY REGION, 2020-2027 (USD MILLION) 55
-
URINARY TRACT INFECTION MARKET, BY REGION, 2020-2027 (USD MILLION) 57
-
AMERICAS: URINARY TRACT INFECTION MARKET, BY REGION, 2020-2027 (USD MILLION)
-
2027 (USD MILLION) 58
-
MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 59
-
AMERICAS: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS,
-
BY TYPE, 2020-2027 (USD MILLION) 59
-
INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 60
-
AMERICAS: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 60
-
(USD MILLION) 60
-
BY COUNTRY, 2020-2027 (USD MILLION) 61
-
TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 61
-
NORTH AMERICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027
-
(USD MILLION) 62
-
FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 62
-
(USD MILLION) 63
-
BY PATHOGEN, 2020-2027 (USD MILLION) 63
-
TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 63
-
NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD
-
MILLION) 64
-
BY TYPE, 2020-2027 (USD MILLION) 64
-
MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION)
-
(USD MILLION) 65
-
2027 (USD MILLION) 66
-
BY END USER, 2020-2027 (USD MILLION) 66
-
INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 67
-
CANADA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD
-
MILLION) 67
-
& CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 68
-
URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 68
-
(USD MILLION) 69
-
BY DRUG CLASS, 2020-2027 (USD MILLION) 70
-
TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 70
-
CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 71
-
URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 72
-
(USD MILLION) 72
-
BY END USER, 2020-2027 (USD MILLION) 72
-
INFECTION MARKET, BY REGION, 2020-2027 (USD MILLION) 73
-
URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 73
-
(USD MILLION) 74
-
Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 74
-
MILLION) 75
-
2027 (USD MILLION) 75
-
BY END USER, 2020-2027 (USD MILLION) 75
-
TRACT INFECTION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 76
-
WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD
-
MILLION) 77
-
FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 77
-
EUROPE: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS,
-
BY TYPE, 2020-2027 (USD MILLION) 78
-
TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 78
-
WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION)
-
2027 (USD MILLION) 79
-
MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 80
-
TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 80
-
BY TYPE, 2020-2027 (USD MILLION) 81
-
MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 81
-
URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 82
-
MILLION) 82
-
CLASS, 2020-2027 (USD MILLION) 83
-
MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 83
-
FRANCE: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS,
-
BY TYPE, 2020-2027 (USD MILLION) 84
-
MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 84
-
TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 85
-
FRANCE: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION)
-
(USD MILLION) 86
-
BY TYPE, 2020-2027 (USD MILLION) 86
-
MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION)
-
(USD MILLION) 87
-
2027 (USD MILLION) 88
-
BY END USER, 2020-2027 (USD MILLION) 88
-
INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 89
-
ITALY: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION)
-
& CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 90
-
URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 90
-
(USD MILLION) 91
-
CLASS, 2020-2027 (USD MILLION) 92
-
MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 92
-
SPAIN: URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY
-
TYPE, 2020-2027 (USD MILLION) 93
-
MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 93
-
TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 94
-
SPAIN: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION)
-
BY DRUG CLASS, 2020-2027 (USD MILLION) 95
-
URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION)
-
FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 96
-
2027 (USD MILLION) 96
-
TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 97
-
REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027
-
(USD MILLION) 97
-
BY DRUG CLASS, 2020-2027 (USD MILLION) 98
-
TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 98
-
CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 99
-
EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
-
2027 (USD MILLION) 100
-
MARKET, BY END USER, 2020-2027 (USD MILLION) 100
-
URINARY TRACT INFECTION MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 101
-
(USD MILLION) 102
-
FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 102
-
URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE,
-
2027 (USD MILLION) 103
-
MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 103
-
URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 104
-
(USD MILLION) 104
-
DRUG CLASS, 2020-2027 (USD MILLION) 105
-
INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 105
-
BY TYPE, 2020-2027 (USD MILLION) 106
-
MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 106
-
URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 107
-
(USD MILLION) 108
-
QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 108
-
TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027
-
(USD MILLION) 109
-
APPLICATION, 2020-2027 (USD MILLION) 109
-
INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 110
-
INDIA: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 110
-
(USD MILLION) 111
-
QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 111
-
TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027
-
(USD MILLION) 112
-
APPLICATION, 2020-2027 (USD MILLION) 112
-
INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 113
-
JAPAN: URINARY TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 113
-
(USD MILLION) 114
-
FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 114
-
URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE,
-
2027 (USD MILLION) 115
-
MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 115
-
URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 116
-
MILLION) 116
-
DRUG CLASS, 2020-2027 (USD MILLION) 117
-
TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD MILLION) 117
-
& CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 118
-
SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
-
2027 (USD MILLION) 119
-
MARKET, BY END USER, 2020-2027 (USD MILLION) 119
-
URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 120
-
BY TYPE, 2020-2027 (USD MILLION) 120
-
URINARY TRACT INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE,
-
2027 (USD MILLION) 121
-
INFECTION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 121
-
REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD
-
MILLION) 122
-
MARKET, BY END USER, 2020-2027 (USD MILLION) 122
-
& AFRICA: URINARY TRACT INFECTION MARKET, BY REGION, 2020-2027 (USD MILLION)
-
BY DRUG CLASS, 2020-2027 (USD MILLION) 123
-
AFRICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027 (USD
-
MILLION) 124
-
MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION)
-
BY APPLICATION, 2020-2027 (USD MILLION) 125
-
AFRICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 125
-
USER, 2020-2027 (USD MILLION) 125
-
INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION) 126
-
MIDDLE EAST: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2020-2027
-
(USD MILLION) 126
-
FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD MILLION) 127
-
(USD MILLION) 127
-
BY PATHOGEN, 2020-2027 (USD MILLION) 128
-
TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 128
-
AFRICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
-
BY TYPE, 2020-2027 (USD MILLION) 129
-
INFECTION MARKET, FOR Β-LACTAM & CEPHALOSPORINS, BY TYPE, 2020-2027 (USD
-
MILLION) 130
-
2027 (USD MILLION) 130
-
MARKET, BY PATHOGEN, 2020-2027 (USD MILLION) 131
-
TRACT INFECTION MARKET, BY END USER, 2020-2027 (USD MILLION) 131
-
MAJOR MANUFACTURERS RANKING, 2020 134
-
AND LAUNCHES 134
-
INC.: PRODUCTS/SERVICES OFFERED 138
-
OFFERED 141
-
ELI LILY AND COMPANY: PRODUCTS/SERVICES OFFERED 148
-
PRODUCTS/SERVICES OFFERED 150
-
OFFERED 151
-
TEVA PHARMACEUTICALS: PRODUCTS/SERVICES OFFERED 154
-
PHARMACEUTICALS: KEY DEVELOPMENTS 154
-
PRODUCTS/SERVICES OFFERED 157
-
LIST OF
-
ANALYSIS, BY REGION, 2020 18
-
MARKET: STRUCTURE 19
-
(UTI) MARKET 29
-
RESTRAINT IMPACT ANALYSIS 32
-
INFECTION MARKET 33
-
URINARY TRACT INFECTION MARKET 35
-
MARKET, BY DRUG CLASS, 2020 AND 2027 (USD MILLION) 41
-
URINARY TRACT INFECTION MARKET, BY APPLICATION, 2020 AND 2027 (USD MILLION) 46
-
(USD MILLION) 49
-
END USER, 2020 AND 2027 (USD MILLION) 53
-
INFECTION MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 57
-
AMERICAS: URINARY TRACT INFECTION MARKET SHARE, BY REGION, 2020 (%) 58
-
SHARE, BY COUNTRY, 2020 (%) 76
-
INFECTION MARKET SHARE, BY COUNTRY, 2020 (%) 101
-
& AFRICA: URINARY TRACT INFECTION MARKET SHARE, BY REGION, 2020 (%) 123
-
OPERATING INCOME MARGIN, 2020 135
-
EXPENDITURE, 2020 135
-
NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT 140
-
SWOT ANALYSIS 141
-
& CO., INC.: FINANCIAL OVERVIEW SNAPSHOT 145
-
CO., INC.: SWOT ANALYSIS 146
-
OVERVIEW SNAPSHOT 147
-
ALLERGAN: SWOT ANALYSIS 150
-
PLC: FINANCIAL OVERVIEW SNAPSHOT 156
-
ANALYSIS 157